Molecular phenotypes and clinical characterization of familial hereditary breast cancer among half and full sisters

Table 7 Comparison of enzyme-labeled staining for HER-2 and Ki-67 across subgroups

Variable	NHBC	HBC			Total
Variable	NHBC	CHBC	NCHBC	CHBC + NCHBC	Total
Expression of HER-2, n	152	18	20	38	190
(−)(±)	88	8	11	19	107
(+)(++) (+++)	64	10	9	19	83
	X² = 0.77 P > 0.05	X² = 1.18 *P > 0.05	X² = 0.06 **P > 0.05	X² = 0.45 ^#P > 0.05
(−)(±)(+)	104	10	14	24	128
(++)(+++)	48	8	6	14	62
	X² = 0.38 P > 0.05	X² = 1.21 *P > 0.05	X² = 0.02 **P > 0.05	X² = 0.85 ^#P > 0.05
(−)(±)(+)(++)	144	13	18	31	175
(+++)	8	5	2	7	15
	X² = 7.24 P < 0.01	X² = 11.55 *P < 0.001	X² = 0.72 **P > 0.05	X² = 0.99 ^#P > 0.05
Expression of Ki-67, n
(−)	36	6	7	13	49
(+)(++)(+++)	116	12	13	25	141
	X² = 3.07 P > 0.05	X² = 2.46 *P > 0.05	X² = 1.23 **P > 0.05	X² = 0.42 ^#P > 0.05
(−)(+)	72	8	10	18	90
(++) (+++)	80	10	10	20	100
	X² = 1.76 P > 0.05	X² = 0.81 *P > 0.05	X² = 1.2 **P > 0.05	X² = 0.01 ^#P > 0.05

HBC hereditary breast cancer, NHBC non-hereditary breast cancer, CHBC contemporaneous hereditary breast cancer, NCHBC non-contemporaneous hereditary breast cancer
HER-2, (−): less than 1% staining, (+): 1–30% staining, (++): 30–80% staining, (+++): more than 80% staining, (±) fish negative, HER-2 gene non-amplification, (+) fish positive, HER-2 gene amplification; for Ki-67: (−): less than 14% staining, (+): 15–25% staining, (++): 25–50% staining, (+++): more than 50% staining. P = NHBC versus HBC, *P = NHBC versus CHBC, **P = NHBC versus NCHBC, ^#P = CHBC versus NCHBC

ISSN: 1472-6874